Skip to main content

Part of the book series: Current Clinical Practice ((CCP))

  • 1005 Accesses

Abstract

Polycystic Ovary Syndrome (PCOS) is the one of the common cause of menstrual irregularity in the United States and a leading cause of infertility. PCOS prevalence ranges from 6 to 10% in the United States. Because obesity may unmask PCOS, the incidence may increase as obesity rates increase. PCOS has been viewed as a collection of reproductive disorders, including polycystic ovaries, anovulation, infertility, and pregnancy loss, associated with hirsutism, acne, and obesity. More recently, PCOS has been linked with cardiovascular risk factors, such as elevated blood pressure, dyslipidemia, abnormal glucose metabolism, and coagulopathies. As many as one-third of PCOS women develop type 2 diabetes. Small observational studies have linked PCOS with early coronary artery disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Zawedzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Polycystic Ovary Syndrome (Dunaif A, Givens JR, Haseltine FP, Merriam GR, eds.). Glasckwell Scientific, Boston, 1992; pp. 377–384.

    Google Scholar 

  2. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81(1):19–25.

    Article  Google Scholar 

  3. Balen A, Michelmore K. What is polycystic ovary syndrome? Hum Repro 2002; 17(9):2219–2227.

    Article  Google Scholar 

  4. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997; 18:774–800.

    Article  CAS  PubMed  Google Scholar 

  5. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38:1165–1174.

    Article  CAS  PubMed  Google Scholar 

  6. Rebar R, Judd HL, Yen SS, Rakoff J, Vandenberg G, Naftolin F. Characterization of the inappropriate gonadotropin secretion in polycystic ovarian syndrome. J Clin Invest 1976;57:1320–1329.

    Article  CAS  PubMed  Google Scholar 

  7. Sherif K, Kushner H, Falkner BE. Sex hormone-binding globulin and insulin resistance in African-American women. Metab Clin Experim 1998;47(1):70–74.

    CAS  Google Scholar 

  8. Deaton MA, Glorioso JE, McLean DB. Congenital adrenal hyperplasia: not really a zebra. Amer Fam Physician 1999;59(5):1190–1196.

    CAS  Google Scholar 

  9. Luthold WW, Borges MF, Marcondes JA, Hakohyama M, Wajchenberg BL, Kirschner MA. Serum testosterone fractions in women: normal and abnormal clinical states. Metab Clin Exper 1993;42(5):638–643.

    CAS  Google Scholar 

  10. Sherif K. Benefits and risks of oral contraceptives. Amer J Obstet Gyn 1999;180(6):S343–S348.

    Article  CAS  Google Scholar 

  11. Hull MGR. Epidemiology of infertility and polycystic ovarian disease: endocrinological and demographic studies. Gyn Endocrinol 1987;1:233–245.

    Google Scholar 

  12. Garber AJ, Duncan TJ, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type 2 diabetes: results of a double-blind, placebo-controlled, dose-response trial. Amer J Med 1997;103(6):491–497.

    Article  CAS  PubMed  Google Scholar 

  13. Lord JM, Flight IHK, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 2003;327:951.

    Article  CAS  PubMed  Google Scholar 

  14. Farquhar C, Lee O, Toomath R, Jepson R. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. Cochrane Database of Systematic Reviews. 2001;(4):CD000194.

    Google Scholar 

  15. George SS, George K, Irwin C, et al. Sequential treatment of metformin and clomiphene citrate in clomiphene-resistant women with polycystic ovary syndrome: a randomized, controlled trial. Human Repro 2003;18(2):299–304.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Sherif, K. (2008). Polycystic Ovary Syndrome. In: Clouse, A.L., Sherif, K. (eds) Women’s Health in Clinical Practice. Current Clinical Practice. Humana Press. https://doi.org/10.1007/978-1-59745-469-8_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-469-8_10

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-631-3

  • Online ISBN: 978-1-59745-469-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics